Novo Nordisk at NYSE on World Diabetes Day

Novo Nordisk (NYSE-Listed NVO) visited the NYSE to recognize World Diabetes Day and commemorated the company’s 30th anniversary of trading on the NYSE. In honor of the occasion, President and CEO Lars Rebien Sørensen rang The Closing BellSM.

With close to 51% market share, Novo Nordisk is the world’s leading manufacturer of insulin and is working to change the way diabetes is prevented, treated and managed. In the U.S., Novo Nordisk currently employs a workforce of more than 4,000 with its American headquarters in Princeton, NJ. The company recently submitted insulin degludec, its newest generation insulin, to the FDA for approval.

In the U.S., the CDC estimates that diabetes affects 25.8 million people (8.3% of the U.S. population) and costs the U.S. economy $174 billion annually, including $116 billion in direct medical expenses. Current estimates from the International Diabetes Federation put the number of people around the world with diabetes at 366 million. (Source: Novo Nordisk)

About Novo Nordisk (NYSE: NVO)

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries. For more information, visit

About World Diabetes Day

World Diabetes Day is celebrated every year on November 14. The World Diabetes Day campaign is led by the International Diabetes Federation (IDF) and its member associations. It engages millions of people worldwide in diabetes advocacy and awareness. World Diabetes Day was created in 1991 by the International Diabetes Federation and the World Health Organization in response to growing concerns about the escalating health threat that diabetes now poses. World Diabetes Day became an official United Nations Day in 2007 with the passage of United Nation Resolution 61/225. The campaign draws attention to issues of paramount importance to the diabetes world and keeps diabetes firmly in the public spotlight.